Publications by authors named "Navdeep Pal"

Claim this Profile
I
Identification of non-actionable mutations with prognostic and predictive value in patients with advanced or metastatic non-small cell lung cancer.
Mariano Provencio-Pulla, Diego Pérez-Parente, Sara Olson, Haroon Hasan, Begoña Campos Balea, Navdeep Pal

Clin Transl Oncol· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Systematic analysis of off-label and off-guideline cancer therapy usage in a real-world cohort of 165,912 US patients.
Ruishan Liu, Lisa Wang, Shemra Rizzo, Marius Rene Garmhausen, Navdeep Pal

Cell Rep Med· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Applying the estimand and target trial frameworks to external control analyses using observational data: a case study in the solid tumor setting.
Letizia Polito, Qixing Liang, Navdeep Pal, Philani Mpofu, Ahmed Sawas

Front Pharmacol· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-World Comparative Effectiveness of First-Line Alectinib Versus Crizotinib in Patients With Advanced -Positive NSCLC With or Without Baseline Central Nervous System Metastases.
Qing Zhang, Jessica J Lin, Navdeep Pal, Letizia Polito, Huong Trinh

JTO Clin Res Rep· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Overall survival in patients with advanced non-small cell lung cancer with KRAS G12C mutation with or without STK11 and/or KEAP1 mutations in a real-world setting.
Cristina Julian, Navdeep Pal, Anda Gershon, Marie Evangelista, Hans Purkey

BMC Cancer· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Systematic pan-cancer analysis of mutation-treatment interactions using large real-world clinicogenomics data.
Ruishan Liu, Shemra Rizzo, Sarah Waliany, Marius Rene Garmhausen, Navdeep Pal

Nat Med· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Replication of Overall Survival, Progression-Free Survival, and Overall Response in Chemotherapy Arms of Non-Small Cell Lung Cancer Trials Using Real-World Data.
Thanh G N Ton, Navdeep Pal, Huong Trinh, Sami Mahrus, Michael T Bretscher

Clin Cancer Res· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Machine Learning Prediction of Clinical Trial Operational Efficiency.
Kevin Wu, Eric Wu, Michael DAndrea, Nandini Chitale, Melody Lim, Navdeep Pal

AAPS J· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluating eligibility criteria of oncology trials using real-world data and AI.
Ruishan Liu, Shemra Rizzo, Samuel Whipple, Navdeep Pal, Arturo Lopez Pineda

Nature· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prospective phase II trial of levonorgestrel intrauterine device: nonsurgical approach for complex atypical hyperplasia and early-stage endometrial cancer.
Shannon N Westin, Bryan Fellman, Charlotte C Sun, Russell R Broaddus, Misty L Woodall, Navdeep Pal

Am J Obstet Gynecol· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment of Low-Risk Endometrial Cancer and Complex Atypical Hyperplasia With the Levonorgestrel-Releasing Intrauterine Device.
Navdeep Pal, Russell R Broaddus, Diana L Urbauer, Nyla Balakrishnan, Andrea Milbourne

Obstet Gynecol· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Factors prognostic of survival in advanced-stage uterine serous carcinoma.
Laura L Holman, Navdeep Pal, David A Iglesias, Pamela T Soliman, Nyla Balakrishnan

Gynecol Oncol· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PTEN loss is a context-dependent outcome determinant in obese and non-obese endometrioid endometrial cancer patients.
Shannon N Westin, Zhenlin Ju, Russell R Broaddus, Camilla Krakstad, Jane Li, Navdeep Pal

Mol Oncol· October 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Overall survival after pelvic exenteration for gynecologic malignancy.
Shannon N Westin, Vijayashri Rallapalli, Bryan Fellman, Diana L Urbauer, Navdeep Pal

Gynecol Oncol· September 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis